In recent retrospective studies, BRCA1/2 germline mutations were associated with significantly worse outcomes after definitive local therapy for PCa with a median cancer-specific survival of 8.6 years compared to 15.7 years in non-carriers (p < 0.01) [30]. The gene discussed is BRCA1; the disease is cancer.